CPHL1P and prostate cancer: Different from CMAHP, higher expression of unitary pseudogene CPHL1P was associated with worse patient OS (log-rank test, p = 4.98 × 10-6) in clear cell renal cell carcinoma (KIRC) and worse patient RFS (log-rank test, p = 0.00245) in prostate cancer (PRAD), respectively (Fig. 6E).